nach oben

Erschienen in:

01.10.2014 | Guidelines

Acute-on-chronic liver failure: consensus recommendations of the Asian Pacific Association for the Study of the Liver (APASL) 2014

Erschienen in: Hepatology International | Ausgabe 4/2014

Einloggen, um Zugang zu erhalten

Abstract

The first consensus report of the working party of the Asian Pacific Association for the Study of the Liver (APASL) set up in 2004 on acute-on-chronic liver failure (ACLF) was published in 2009. Due to the rapid advancements in the knowledge and available information, a consortium of members from countries across Asia Pacific, “APASL ACLF Research Consortium (AARC),” was formed in 2012. A large cohort of retrospective and prospective data of ACLF patients was collated and followed up in this data base. The current ACLF definition was reassessed based on the new AARC data base. These initiatives were concluded on a 2-day meeting in February 2014 at New Delhi and led to the development of the final AARC consensus. Only those statements which were based on the evidence and were unanimously recommended were accepted. These statements were circulated again to all the experts and subsequently presented at the annual conference of the APASL at Brisbane, on March 14, 2014. The suggestions from the delegates were analyzed by the expert panel, and the modifications in the consensus were made. The final consensus and guidelines document was prepared. After detailed deliberations and data analysis, the original proposed definition was found to withstand the test of time and identify a homogenous group of patients presenting with liver failure. Based on the AARC data, liver failure grading, and its impact on the "Golden therapeutic Window," extra-hepatic organ failure and development of sepsis were analyzed. New management options including the algorithms for the management of coagulation disorders, renal replacement therapy, sepsis, variceal bleed, antivirals, and criteria for liver transplantation for ACLF patients were proposed. The final consensus statements along with the relevant background information are presented here.

Sarin SK, Kumar A, Almeida JA, Chawla YK, Fan ST, Garg H, et al. Acute-on-chronic liver failure: consensus recommendations of the Asian Pacific Association for the Study of the liver (APASL). Hepatol Int. 2009;3:269–282PubMedPubMedCentral

Moreau R, Jalan R, Gines P, Pavesi M, Angeli P, Cordoba J, et al. Acute-on-chronic liver failure is a distinct syndrome that develops in patients with acute decompensation of cirrhosis. Gastroenterology. 2013;144:1426–1437PubMed

Centre for evidence-based medicine. Levels of evidence. 2001. http://www.cebm.net/index.aspx?o=1047. Accessed 12 Oct 2008

O’Grady JG, Schalm SW, Williams R. Acute liver failure: redefining the syndromes. Lancet. 1993;342:273–275

Sen S, William R, Jalan R. The pathophysiological basis of acute-on-chronic liver failure. Liver. 2002;22(Suppl 2):5–13PubMed

Wlodzimirow KA, Eslami S, Abu-Hanna A, Nieuwoudt M, Chamuleau RA. A systematic review on prognostic indicators of acute on chronic liver failure and their predictive value for mortality. Liver Int 2013;33(1):40–52PubMed

Ferenci P, Lockwood A, Mullen K, Tarter P, Weissenborn K, Blei AT. Hepatic encephalopathy: definition, nomenclature, diagnosis and quantification—final report of the working party at the 11th World Congress of Gastroenterology, Vienna 1998. Hepatology. 2002;25(3):716–721

Bajaj JS. Defining acute-on-chronic liver failure: will East and West ever meet. Gastroenterology. 2013;144:1337–1339PubMed

Olson JC, Wendon JA, Kramer DJ, Vicente A, Jalan R, Garcia-Tsao G, et al. Intensive care of the patient with cirrhosis. Hepatology. 2011;54:1864–1872PubMed

10.

Xu L, Tu Z, Xu G, Wang Y, Pan W, Zhan X, et al. Epirubicin directly promotes hepatitis B virus (HBV) replication in stable HBV-expressing cell lines: a novel mechanism of HBV reactivation following anticancer chemotherapy. Mol Med Rep 2014;9(4):1345–1350PubMed

11.

Mikulska M, Nicolini L, Signori A, Rivoli G, Bono VD, Raiola AM, et al. Hepatitis B reactivation in HBsAg negative/HBcAb positive allogeneic hematopoietic stem cell transplant recipients: risk factors and outcome. Clin Microbiol Infect. 2014;. doi:10.1111/1469-0691.12611 PubMed

12.

Pei R, Grund S, Verheyen J, Esser S, Chen X, Lu M. Spontaneous reactivation of hepatitis B virus replication in a HIV coinfected patient with isolated anti-Hepatitis B core antibodies. Virol J. 2014;11:9. doi:10.1186/1743-422X-11-9 PubMedPubMedCentral

13.

Magalhaes RK, Ferreira D, Salgado M, Pedroto I. Hepatitis B virus reactivation after chemotherapy in an HIV positive patient. J Clin Gastroenterol 2013;47(6):565–566PubMed

14.

Lim SG, Wai CT, Rajnakova A, Kajiji T, Guan R. Fatal hepatitis B reactivation following discontinuation of nucleoside analogues for chronic hepatitis B. Gut. 2002;51(4):597–599PubMedPubMedCentral

15.

Martin ST, Cardwell SM, Nailor MD, Gabardi S. Hepatitis B reactivation and rituximab: a new boxed warning and considerations for solid organ transplantation. Am J Transplant. 2014;. doi:10.1111/ajt.12649

16.

Kusumoto S, Tanaka Y, Mizokami M, Ueda R. Strategy for preventing hepatitis B reactivation in patients with resolved HBV infection following rituximab containing chemotherapy. Hepatology. 2013;. doi:10.1002/hep.26963

17.

Tsutsumi Y, Yamamoto Y, Shimono J, Ohhigashi H, Teshima T. Hepatitis B virus reactivation with rituximab containing regimen. World J Hepatol 2013;5(11):612–662PubMedPubMedCentral

18.

Huang M, Huang L. Reactivation of Hepatitis C viral infection after treatment with infliximab. J Clin Gastroenterol 2014;48(2):189–190PubMed

19.

Sagnelli E, Pisaturo M, Stanzione M, Messina V, Alessio L, Sagnelli C, et al. Clinical presentation, outcome and response to therapy among patients with acute exacerbation of chronic hepatitis C. Clin Gastroenterol Hepatol 2013;11(9):1174–1180PubMed

20.

Radha Krishna Y, Saraswat VA, Das K, Himanshu G, Yachha SK, Aggarwal R, et al. Clinical features and predictors of outcome in acute hepatitis A and hepatitis E virus hepatitis on cirrhosis. Liver Int 2009;29(3):392–398PubMed

21.

Mahtab MA, Rahman S, Khan M, Karim MF. Hepatitis E virus is a leading cause of acute-on-chronic liver disease: experience from a tertiary center in Bangladesh. Hepatobiliary Pancreat Dis Int. 2009; 8(1): 50–52

22.

Kumar M, Sharma BC, Sarin SK. Hepatitis E virus as an etiology of acute exacerbation of previously unrecognized asymptomatic patients with hepatitis B virus related chronic liver disease. J Gastroenterol Hepatol 2008;23(6):83–87

23.

Acharya SK, Sharma PK, Singh R, Mohanty SK, Madan K, Jha JK, et al. Hepatitis E virus (HEV) infection in patients with cirrhosis is associated with rapid decompensation and death. J Hepatol 2007;46:387–394

24.

Kim AY, Chung RT. Bacterial, parasitic and fungal infections of the liver, including liver abscess. In Feldman M, Friedman L, Brandt LJ, editors. Sleisenger and Fordtran’s Gastrointestinal and Liver Disease. 9th ed. Philadelphia: WB Saunders; 2010. 1351

25.

Moreau R, Arroyo V. Acute-on-chronic liver failure: a new clinical entity. Clin Gastroenterol Hepatol. 2014;. doi:10.1016/j.cgh.2014.02.027

26.

Garg H, Kumar A, Garg V, Sharma P, Sharma BC, Sarin SK. Clinical profile and predictors of mortality in patients of acute-on-chronic liver failure. Dig Liver Dis 2012;44(2):166–171PubMed

27.

Wasmuth HE, Kunz D, Yagmur E, Timmer-Stranghöner A, Vidacek D, Siewert E, et al. Patients with acute-on-chronic liver failure display “sepsis-like” immune paralysis. J Hepatol 2005;42(2):195–201PubMed

28.

Duseja A, Chawla YK, Dhiman RK, Kumar A, Choudhary N, Taneja S. Non-Hepatic insults are common precipitants in patients with acute-on-chronic liver failure. Dig Dis Sci 2010;55(11):3188–3192PubMed

29.

Ripoll C, Groszmann R, Garcia-Tsao G, Grace N, Burroughs A, Planas R, et al. Hepatic pressure gradient predicts clinical decompensation in patients with compensated cirrhosis. Gastroenterol 2007;133:481–488

30.

Amitrano L, Guardascione MA, Martino R, Manguso F, Menchise A, Balzano A. Hypoxic hepatitis occurring in cirrhosis after variceal bleeding: still a lethal disease. J Clin Gastroenterol 2012;46(7):608–612PubMed

31.

Bruns T, Zimmermann HW, Stallmach A. Risk factors and outcome of bacterial infections in cirrhosis. World J Gastroenterol 2014;20(10):2542–2554PubMedPubMedCentral

32.

Desmet VJ, Roskams T. Cirrhosis reversal: a duel between dogma and myth. J Hepatol 2004;40:860–867PubMed

33.

Wanless IR, Wong F, Blendis LM, Greig P, Heathcote EJ, Levy G. Hepatic and portal vein thrombosis in cirrhosis: possible role in development of parenchymal extinction and portal hypertension. Hepatology. 1995;21(5):1238–1247PubMed

34.

Kim MY, Cho MY, Baik SK, Park HJ, Jeon HK, Im CK, et al. Histological subclassification of cirrhosis using the Laennac fibrosis scoring system correlates with clinical stage and grade of portal hypertension. J Hepatol 2011;55(5):1004–1009PubMed

35.

Rastogi A, Maiwall R, Bihari C, Ahuja A, Kumar A, Singh T, et al. Cirrhosis etiology and laennac staging system correlate with high portal pressure. Histopathology. 2013;62(5):731–741PubMed

36.

Libbrecht L, Desmet V, Van Damme B, Roskams T. Deep intralobular extension of human hepatic “progenitor cells” correlates with parenchymal inflammation in chronic viral hepatitis: can “progenitor cells” migrate? J Pathol 2000;192:373–378PubMed

37.

de Graaf EL, Kench J, Dilworth P, Shackel NA, Strasser SL, Joseph D, et al. Grade of deceased donor liver macrovesicular steatosis impacts graft and recipient outcomes more than the donor risk index. J Gastroenterol Hepatol 2012;27(3):540–546PubMed

38.

Gabrielli M, Moisan F, Vidal M, Duarte I, Jiménez M, Izquierdo G, et al. Steatotic livers. Can we use them in OLTX? Outcome data from a prospective baseline liver biopsy study. Ann Hepatol 2012;11(6):891–898PubMed

39.

Angulo P, Keach JC, Batts KP, Lindor KD. Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis. Hepatology. 1999;30(6):1356–1362PubMed

40.

Loomba R, Sanyal A. The global NAFLD epidemic. Nat Rev Gastroenterol Hepatol 2013;10(11):686–690PubMed

41.

Laleman W, Verbeke L, Meersseman P, Wauters J, van Pelt J, Cassiman D, et al. Acute-on-chronic liver failure: current concepts on definition, pathogenesis, clinical manifestations and potential therapeutic interventions. Expert Rev Gastroenterol Hepatol 2011;5(4):523–537PubMed

42.

Rastogi A, Kumar A, Sakhuja P, Bihari C, Gondal R, Hissar S, et al. Liver histology as predictor of outcome in patients with acute-on-chronic liver failure (ACLF). Virchows Arch 2011;459(2):121–127PubMed

43.

Kalambokis G, Manousou P, Vibhakorn S, Marelli L, Cholongitas E, Senzolo M, et al. Transjugular liver biopsy: indications, adequacy, quality of specimens, and complications—a systematic review. J Hep 2007;47:284–294

44.

Myers RP, Elkashab M, Ma M, et al. Transient elastography for noninvasive assessment of liver fibrosis: a multicenter Canadian study. Can J Gastroenterol 2010;24(11):661–670PubMedPubMedCentral

45.

Kedarisetty CK, Bhardwaj A, Garg H, Wagle P, Sarin SK. Reduction in liver stiffness at one month is a predictor of survival in acute-on-chronic liver failure. Presented as poster at APASL annual conference 2014 Brisbane

46.

Jha AK, Nijhawan S, Rai RR, Nepalia S, Jain P, Suchismita A. Etiology, clinical profile and inhospital mortality of acute-on-chronic liver failure: a prospective study. Indian J Gastroenterol 2013;32(2):108–114PubMed

47.

Seto WK, Lai CL, Yuen MF. Acute-on-chronic liver failure in chronic hepatitis B. J Gastroenterol Hepatol 2012;27(4):662–669PubMed

48.

Adams LA, Lymp JF, Sanderson SO, Lindor KD, Feldstein A, Angulo P. The natural history of nonalcoholic fatty liver disease: a population based cohort study. Gastroenterology. 2005;129:113–121PubMed

49.

Caldwell SH, Crespo DM. The spectrum expanded: cryptogenic cirrhosis and natural history of nonalcoholic fatty liver disease. J Hepatol 2004;40:578–584PubMed

50.

Bhala N, Angulo P, Van der Poorten D, Lee E, Hui JM, Saracco G, et al. The natural history of nonalcoholic fatty liver disease with advanced fibrosis or cirrhosis: an international collaborative study. Hepatology. 2011;54:1208–1216PubMedPubMedCentral

51.

Sheth SG, Flamm SL, Gordon FD, Chopra S. AST/ALT ratio predicts cirrhosis in patients with chronic hepatitis C virus infection. Am J Gastroenterol 1998;93(1):44–48PubMed

52.

Kruger FC, Daniels CR, Kidd M, Swart G, Brundyn K, van Rensberg C, et al. APRI: a simple bedside marker of advanced fibrosis that can avoid liver biopsy in patients with NAFLD/NASH. S Afr Med J 2011;101(7):477–480PubMed

53.

Katoonizadeh A, Laleman W, Verslype C, Wilmer A, Maleux G, Roskams T, et al. Early features of acute-on-chronic alcoholic liver failure: a prospective cohort study. Gut. 2010;59(11):1561–1569PubMed

54.

Jalan R, Mookerjee RP. Acute-on-chronic liver failure: an early liver biopsy is essential? Gut. 2010;59(11):1455–1456PubMed

55.

Rastogi A, Maiwall R, Bihari C, Trehanpati N, Pamecha V, Sarin SK. Two-tier regenerative response in liver failure in humans. Virchows Arch. 2014;464(5):565–573

56.

Rastogi A, Bihari C, Maiwall R, Ahuja A, Sharma MK, Kumar A, et al. Hepatic stellate cells are involved in the pathogenesis of acute-on-chronic liver failure. Virchows Arch 2012;461(4):393–398PubMed

57.

Garg V, Garg H, Khan A, Trehanpati N, Kumar A, Sharma BC, et al. Granulocyte colony stimulating factor mobilizes CD 34 + cells and improves survival of patients with acute-on-chronic liver failure. Gastroenterology. 2012;142(3):505–512PubMed

58.

Jalan R, Gines P, Olson JC, Mookerjee RP, Moreau R, Garcia-Tsao G, et al. Acute-on chronic liver failure. J Hepatol 2012;57(6):1336–1348PubMed

59.

Kar R, Kar SS, Sarin SK. Hepatic coagulopathy—intricacies and challenges; a cross-sectional descriptive study of 110 patients from a superspeciality institute in North India with review of literature. Blood Coag Fibrinolysis 2013;24(2):175–180

60.

Lisman T, Leebeck FW. Hemostatic alterations in liver disease: a review of pathophysiology, clinical consequences and treatment. Dig Surg 2007;24(4):250–258PubMed

61.

Saxena P, Bihari C, Rastogi A, Agarwal S, Anand L, Sarin SK. Sonoclot signature analysis in patients with liver disease with conventional coagulation studies. Adv Hematol 2013;2013:23751

62.

Trey C, Davidson CS. The management of fulminant hepatic failure. In Popper H, Schaffner F, editors. Progress in Liver Diseases. New York: Grune & Stratton; 1970. 282–298

63.

Stravitz RT, Lisman T, Luketic VA, Sterling RK, Puri P, Fuchs M, et al. Minimal effects of acute liver injury/acute liver failure on hemostasis as assessed by thromboelastography. J Hepatol 2011;56:129–136PubMed

64.

Luddington R, Baglin T. Clinical measurement of thrombin generation by calibrated automated thrombography requires contact factor inhibition. J Thromb Haemostat 2004;2(11):1954–1959

65.

Ninivaggi M, Apitz-Castro R, Dargaud Y, de Laat B, Hemker HC, Lindhout T. Whole blood thrombin generation monitored with a calibrated automated thrombogram based assay. Clin Chem 2012;58(8):1252–1259PubMed

66.

New York Heart Association Inc. New York Heart association classification of Heart failure. In Diseases of the Heart and Blood Vessels: Nomenclature and Criteria for Diagnosis, 6th ed. Boston, Little Brown, 1964. 114

67.

Levy MM, Fink MP, Marshall JC, Abraham E, Angus D, Cook D, et al. 2001 SCCM/ESICM/ACCP/ATS/SIS international sepsis definitions conference. Crit Care Med 2003;31:1250–1256PubMed

68.

Gustot T, Felleiter P, Pickkers P, Sakr Y, Rello J, Velissaris D et al. Impact of infection on the prognosis of critically ill cirrhotic patients: Results from a large worldwide study. Liver Int 2014. doi: 10.1111/liv.12520

69.

Arvaniti V, D’Amico G, Fede G, Manousou P, Tsochatzis E, Plequezuelo M, et al. Infections in patients with cirrhosis increase mortality four- fold and should be used in determining prognosis. Gastroenterology. 2010;139:1246–1256PubMed

70.

Duseja A, Choudhary NS, Gupta S, Dhiman RK, Chawla YK. APACHE II score is superior to SOFA, CTP and MELD in predicting the short term mortality in patients with acute-on-chronic liver failure (ACLF). J Dig Dis 2013;14(9):484–490PubMed

71.

Jalan R, Stadlbauer V, Sen S, Cheshire L, Chang YM, Mookerjee RP. Role of predisposition, injury, response and organ failure in the prognosis of patients with acute-on-chronic liver failure: a prospective cohort study. Crit Care 2012;16(6):R227PubMedPubMedCentral

72.

Granja C, Póvoa P, Lobo C, Teixeira-Pinto A, Carneiro A, Costa-Pereira A. The predisposition, infection, response and organ failure (Piro) sepsis classification system: results of hospital mortality using a novel concept and methodological approach. PLoS ONE. 2013;8(1):e53885. doi:10.1371/journal.pone.0053885 PubMedPubMedCentral

73.

Hotchkiss RS, Monneret G, Payen D. Sepsis induced immunosuppression: from cellular dysfunctions to immunotherapy. Nat Rev Immunol 2013;13(12):862–874PubMed

74.

Kox WJ, Volk T, Kox SN, Volk HD. Immunomodulatory therapies in sepsis. Intensive Care Med 2000;26(Suppl 1):S124–S128PubMed

75.

Khanam A, Trehanpati N, Garg V, Kumar C, Garg H, Sharma BC, et al. Altered frequencies of dendritic cells and IFN- γ secreting T cells with granulocyte colony stimulating factor (GCSF) therapy in acute-on-chronic liver failure. Liver Int 2014;34(4):505–513PubMed

76.

Gines P, Schrier RW. Renal failure in cirrhosis. N Engl J Med 2009;361:1279–1290PubMed

77.

Martín-Llahí M, Guevara M, Torre A, Fagundes C, Restuccia T, Gilabert R, et al. Prognostic importance of the cause of renal failure in patients with cirrhosis. Gastroenterology. 2011;140:488–496PubMed

78.

Stadlbauer V, Wright G, Banaji M, Mukhopadhyay A, Mookerjee R, Moore K, et al. Relationship between activation of the sympathetic nervous system and renal blood flow autoregulation in cirrhosis. Gastroenterology. 2008;134:111–119PubMed

79.

Kumar A, Das K, Sharma P, Mehta V, Sharma BC, Sarin SK. Hemodynamic studies in acute-on-chronic liver failure. Dig Dis Sci. 2009;54(4):869–78. doi:10.1007/s10620-008-0421-9 PubMed

80.

Cárdenas A, Ginès P. Acute-on-chronic liver failure: the kidneys. Curr Opin Crit Care 2011;17(2):184–189PubMed

81.

Ros J, Clària J, To-Figueras J, et al. Endogenous cannabinoids: a new system involved in the homeostasis of arterial pressure in experimental cirrhosis in the rat. Gastroenterology. 2002;122:85–93PubMed

82.

Altamirano J, Fagundes C, Dominguez M, García E, Michelena J, Cárdenas A, et al. Acute kidney injury is an early predictor of mortality for patients with alcoholic hepatitis. Clin Gastroenterol Hepatol 2012;10(1):65–71PubMed

83.

Cazzaniga M, Dionigi E, Gobbo G, Fioretti A, Monti V, Salerno F. The systemic inflammatory response syndrome in cirrhotic patients: relationship with their in-hospital outcome. J Hepatol 2009;51:475–482PubMed

84.

Thabut D, Massard J, Gangloff A, Carbonell N, Francoz C, Nguyen-Khac E, et al. Model for end-stage liver disease score and systemic inflammatory response are major prognostic factors in patients with cirrhosis and acute functional renal failure. Hepatology. 2007;46:1872–1882PubMed

85.

Holt S, Goodier D, Marley R, Patch D, Burroughs A, Fernando B, Harry D, et al. Improvement in renal function in hepatorenal syndrome with N-acetylcysteine. Lancet. 1999;353:294–295PubMed

86.

Akriviadis E, Bolta R, Briggs W, et al. Pentoxifylline improves short-term survival in severe alcoholic hepatitis: a double-blind, placebo-controlled trial. Gastroenterology. 2000;119:1637–1648PubMed

87.

Jindal A, Sarin SK. Acute kidney injury (AKI) at admission and its response to terlipressin as a predictor of mortality in patients with acute-on-chronic liver failure (ACLF). J Hepatol. 2013;58(S1):S89

88.

Maiwall R, Kumar S, Vashishtha C, Kumar M, Garg H, Nayak S et al. Acute kidney injury (AKI) in patients with acute-on-chronic liver failure (ACLF) is different from patients with cirrhosis. Hepatology. 2013;58(4), Suppl 36A–91A

89.

Wan ZH, Wang JJ, You SL, Liu HL, Zhu B, Zang H, et al. Cystatin C is a biomarker for predicting acute kidney injury in patients with acute-on-chronic liver failure. World J Gastroenterol 2013;19(48):9432–9438PubMedPubMedCentral

90.

Xing T, Zhong L, Chen D, Peng Z. Experience of combined liver–kidney transplantation for acute-on-chronic liver failure with renal dysfunction. Transplant Proc 2013;45(6):2307–2313PubMed

91.

Donovan JP, Schafer DF, Shaw BW Jr, Sorrell MF. Cerebral edema and increased intracranial pressure in chronic liver disease. Lancet. 1998;351:719–721PubMed

92.

Poveda MJ, Bernabeu A, Concepcion L, et al. Brain edema dynamics in patients with overt hepatic encephalopathy A magnetic resonance imaging study. Neuroimage. 2010;52:481–487PubMed

93.

Shawcross DL, Sharifi Y, Canavan JB, Yeoman AD, Abeles RD, Taylor NJ, et al. Infection and systemic inflammation, not ammonia, are associated with grade 3/4 hepatic encephalopathy, but not mortality in cirrhosis. J Hepatol 2011;54:640–649PubMed

94.

Cordoba J, Ventura-Cots M, Simon-Talero M, Amorós À, Pavesi M, Vilstrup H, et al. Characteristics, risk factors and mortality of cirrhotic patients hospitalized for hepatic encephalopathy with and without acute-on-chronic liver failure. J Hepatol 2014;60:275–281PubMed

95.

Guevara M, Baccaro ME, Torre A. Hyponatremia is a risk factor of hepatic encephalopathy in patients with cirrhosis: a prospective study with time- dependent analysis. Am J Gastroenterol 2009;104:1382–1389PubMed

96.

Chatzicostas C, Roussomoustakaki M, Notas G, Vlachonikolis IG, Samonakis D, Romanos J, et al. A comparison of Child Pugh, APACHE II and APACHE III scoring systems in predicting hospital mortality of patients with liver cirrhosis. BMC Gastroenterol 2003;3:7PubMedPubMedCentral

97.

Chen YC, Tian YC, Liu NJ, Ho YP, Yang C, Chu YY, et al. Prospective cohort study comparing sequential organ failure assessment and acute physiology, age, chronic health evaluation III scoring systems for hospital prediction in critically ill cirrhotic patients. Int J Clin Pract 2006;60(2):160–166PubMed

98.

Kamath PS, Kim WR. The model for end stage liver disease (MELD). Hepatology. 2007;45(3):797–805PubMed

99.

Yu JW, Sun LJ, Zhao YH, Li SC. Prediction value of model for end stage liver disease scoring system on prognosis in patients with acute-on-chronic liver failure after plasma exchange and lamivudine treatment. J Gastroenterol Hepatol 2008;23(8 Pt 1):1242–1249PubMed

100.

Yan Y, Mai L, Zheng YB, Zhang SQ, Xu WX, Gao ZL, et al. What MELD score mandates use of entecavir for ACLF-HBV HBeAg negative patients? World J Gastroenterol 2012;18(33):4604–4609PubMedPubMedCentral

101.

Lai J, Lin CS, Yang L, Chen SR, Zhang YQ, Ke WM. Pretreatment HBsAg level and an early decrease in MELD score predict prognosis to lamivudine treatment for HBeAg negative acute-on-chronic liver failure. Clin Res Hepatol Gastroenterol 2013. doi: 10.1016/j.clinre.2013.10.012

102.

Myers RP, Tandon P, Ney M, Meeberg G, Faris P, Shaheen AA, et al. Validation of the five variable model for Model for End stage Liver disease (5vMELD) for prediction of mortality on liver transplant waiting list. Liver Int. 2013;. doi:10.1111/liv.12373

103.

Bechmann LP, Jochum C, Kocabayoglu P, Sowa JP, Kassalik M, Gieseler RK, et al. Cytokeratin 18 based modification of the MELD score improves prediction of spontaneous survival after acute liver injury. J Hepatol. 2010;53(4):639–47. doi:10.1016/j.jhep.2010.04.029 PubMed

104.

Sun QF, Ding JG, Xu DZ, Chen YP, Hong L, Ye ZY, et al. Prediction of the prognosis of patients with acute-on-chronic hepatitis B liver failure using the model for end stage liver disease scoring system and a novel logistic regression model. J Viral Hepatitis 2009;16:464–470

105.

Zheng MH, Shi KQ, Fan YC, Li H, et al. A model to determine 3-month mortality risk in patients with acute-on-chronic hepatitis B liver failure. Clin Gastroenterol Hepatol 2011;9:351–356PubMed

106.

Lin W, Liu X, Ma L, Wei X, Guo H, Meng Q et al. A Dynamic model for predicting outcome in patients with HBV related acute-on-chronic liver failure. Presented at AASLD The Liver Meeting 2013

107.

Vincent JL, Moreno R, Takala J, Willatts S, De Mendonça A, Bruining H, et al. The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction/failure. Intensive Care Med 1996;22:707–710PubMed

108.

Das V, Boelle PY, Galbois A, Guidet B, Maury E, Carbonell N, et al. Cirrhotic patients in the medical intensive care unit: early prognosis and long-term survival. Crit Care Med 2010;38:2108–2116PubMed

109.

Levesque E, Hoti E, Azoulay D, Ichaï P, Habouchi H, Castaing D, et al. Prospective evaluation of the prognostic scores for cirrhotic patients admitted to an intensive care unit. J Hepatol 2012;56:95–102PubMed

110.

Hoofnagle JH. Reactivation of Hepatitis B. Hepatology. 2009;49:S156–S165PubMed

111.

Jindal A, Kumar M, Sarin SK. Management of acute hepatitis B and reactivation of hepatitis B. Liver Int 2013;33(Suppl 1):164–175PubMed

112.

Sun LJ, Yu JW, Zhao YH, Kang P, Li SC. Influential factors of prognosis in lamivudine treatment for patients with acute-on-chronic hepatitis B liver failure. J Gastroenterol Hepatol 2010;25(3):583–590PubMed

113.

Hwang JP, Lok AS. Management of patients with hepatitis B who require immunosuppressive therapy. Nat Rev Gastroenterol Hepatol. 2013;. doi:10.1038/nrgastro.2013.216 PubMed

114.

115.

Bahirwani R, Shaked O, Bewtra M, Forde K, Reddy KR. Acute-on-chronic liver failure before liver transplantation: impact on post transplant outcomes. Transplantation. 2011;92(8):952–957PubMed

116.

Lin KH, Liu JW, Chen CL, Wang SH, Lin CC, Liu YW, et al. Impacts of pretransplant infections on clinical outcomes of patients with acute-on-chronic liver failure who received living donor liver transplantation. PLoS ONE. 2013;8(9):e72893PubMedPubMedCentral

117.

Chan AC, Fan ST, Lo CM, Liu CL, Chan SC, Ng KK, et al. Liver transplantation for acute-on-chronic liver failure. Hepatol Int 2009;3(4):571–581PubMedPubMedCentral

118.

Chok KSh, Chan SC, Fung JY, Cheung TT, Chan AC, Fan ST, et al. Survival outcomes of right-lobe living donor transplantation for patients with high model for end stage liver disease scores. Hepatobiliary Pancreat Dis Int 2013;12(3):256–262PubMed

119.

Ling Q, Xu X, Wei Q, Liu X, Guo H, Zhuang L, et al. Downgrading MELD improves the outcomes after liver transplantation in patients with acute-on-chronic hepatitis B liver failure. PLoS ONE. 2012;7(1):e30322PubMedPubMedCentral

120.

Xu X, Liu X, Ling Q, Wei Q, Liu Z, Xu X, et al. Artificial liver support system combined with liver transplantation in treatment of patients with acute-on-chronic liver failure. PLoS ONE. 2013;8(3):e58738PubMedPubMedCentral

121.

Duan XZ, Liu FF, Tong JJ, Yang HZ, Chen J, Liu XY, et al. Granulocyte colony stimulating factor therapy improves survival in patients with hepatitis B virus-associated acute-on-chronic liver failure. World J Gastroenterol 2013;19:1104–1110PubMedPubMedCentral

122.

Jalan R, Williams R. Acute-on-chronic liver failure: pathophysiological basis of therapeutic options. Blood Purif 2002;20:252–261PubMed

123.

Hassanein TI, Tofteng F, Brown RS Jr, McGuire B, Lynch P, Mehta R, et al. Randomized controlled study of extracorporeal albumin dialysis for hepatic encephalopathy in advanced cirrhosis. Hepatology. 2007;46(6):1853–1862PubMed

124.

Banares R, Nevens F, Larsen FS, Jalan R, Albillos A, Dollinger M, et al. Extracorporeal albumin dialysis with the molecular adsorbent recirculating system in acute-on-chronic liver failure: the RELIEF trial. Hepatology. 2013;57:1153–1162PubMed

125.

Kribben A, Gerken G, Haag S, Herget-Rosenthal S, Treichel U, Betz C, et al. Effects of fractionated plasma separation and adsorption on survival in patients with acute-on-chronic liver failure. Gastroenterology. 2012;142:782–789PubMed

126.

Mitzner SR, Stange J, Klammt S, Risler T, Erley CM, Bader BD, et al. Improvement of hepatorenal syndrome with extracorporeal albumin dialysis MARS: results of a prospective, randomized, controlled clinical trial. Liver Transplant 2000;6:277–286PubMed

127.

Catalina MV, Barrio J, Anaya F, Salcedo M, Rincón D, Clemente G, Bañares R. Hepatic and systemic haemodynamic changes after MARS in patients with acute on chronic liver failure. Liver Int 2003;23(Suppl 3):39–43PubMed

128.

Laleman W, Wilmer A, Evenepoel P, Elst IV, Zeegers M, Zaman Z, et al. Effect of the molecular adsorbent recirculating system and Prometheus devices on systemic haemodynamics and vasoactive agents in patients with acute-on-chronic alcoholic liver failure. Crit Care 2006;10:R108PubMedPubMedCentral

129.

Guo LM, Liu JY, Xu DZ, Li BS, Han H, Wang LH, et al. Application of Molecular Adsorbents Recirculating System to remove NO and cytokines in severe liver failure patients with multiple organ dysfunction syndrome. Liver Int. 2003;23(Suppl 3):16–20PubMed

130.

Atienza Merino G. Evaluation of extracorporeal liver support systems in the treatment of liver failure: a systematic review. Gastroenterol Hepatol 2010;33(5):352–362PubMed

131.

Kjaergard LL, Liu J, Als-Nielsen B, Gluud C. Artificial and bioartificial support systems for acute and acute-on-chronic liver failure: a systematic review. JAMA. 2003;289(2):217–222PubMed

Titel: Acute-on-chronic liver failure: consensus recommendations of the Asian Pacific Association for the Study of the Liver (APASL) 2014
Publikationsdatum: 01.10.2014
Erschienen in: Hepatology International / Ausgabe 4/2014
Print ISSN: 1936-0533
Elektronische ISSN: 1936-0541
DOI: https://doi.org/10.1007/s12072-014-9580-2

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

25.04.2024 Allergien und Intoleranzreaktionen Nachrichten

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 4/2014

Extended treatment with pegylated interferon alfa/ribavirin in patients with genotype 2/3 chronic hepatitis C who do not achieve a rapid virological response: final analysis of the randomised N-CORE trial

Soluble FGL2, a novel effector molecule of activated hepatic stellate cells, regulates T-cell function in cirrhotic patients with hepatocellular carcinoma

Real-life practice of antiviral therapy and disease patterns of patients with chronic hepatitis B: a single-center retrospective observation study

The natural history of HCV-related cirrhosis and its temporal progression across the different clinical stages

Diagnostic role of radiolabelled choline PET or PET/CT in hepatocellular carcinoma: a systematic review and meta-analysis